Patent ID: 11919953
Assignee: AMGEN INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A  Y | IPC A  C

Claim 12:
13. A composition comprising a CD112R antigen binding protein and a TIGIT antigen binding protein wherein (I) the CD112R antigen binding protein comprises a heavy chain (HC) complementarity-determining region (CDR) 1, HC CDR2, HC CDR3, light chain (LC) CDR1, LC CDR2, and LC CDR3 comprising the amino acid sequences selected from the group consisting of: (a) SEQ ID NOs: 13-18, respectively; (b) SEQ ID NOs: 23-28, respectively; (c) SEQ ID NOs: 33-38, respectively; (d) SEQ ID NOs: 43-48, respectively; (e) SEQ ID NOs: 53-58, respectively; (f) SEQ ID NOs: 63-68, respectively; (g) SEQ ID NOs: 73-78, respectively; (h) SEQ ID NOs: 83-88, respectively; (i) SEQ ID NOs: 93-98, respectively; (j) SEQ ID NOs: 103-108, respectively; (k) SEQ ID NOs: 233-238, respectively; (l) SEQ ID NOs: 1973-1978, respectively; (m) SEQ ID NOs: 1983-1988, respectively; (n) SEQ ID NOs: 1993-1998, respectively; and (o) SEQ ID NOs: 2003-2008, respectively; and/or (II) the TIGIT antigen binding protein comprises a heavy chain (HC) complementarity-determining region (CDR) 1, HC CDR2, HC CDR3, light chain (LC) CDR1, LC CDR2, and LC CDR3 comprising the amino acid sequences selected from the group consisting of: (a) SEQ ID NOs: 113-118, respectively; (b) SEQ ID NOs: 123-128, respectively; (c) SEQ ID NOs: 133-138, respectively; (d) SEQ ID NOs: 143-148, respectively; (e) SEQ ID NOs: 153-158, respectively; (f) SEQ ID NOs: 163-168, respectively; (g) SEQ ID NOs: 173-178, respectively; (h) SEQ ID NOs: 183-188, respectively, (i) SEQ ID NOs: 193-198, respectively; (j) SEQ ID NOs: 203-208, respectively; (k) SEQ ID NOs: 213-218, respectively; (l) SEQ ID NOs: 223-228, respectively; and (m) SEQ ID NOs: 2013-2018, respectively.